With our AI-enabled drug discovery platform and the dedication of our brilliant, hard-working team, we have discovered differentiated therapies for some of the most challenging and pervasive diseases — at record pace.
We’re immensely proud of how far we’ve come since our founding in 2019. And we’re just getting started.
Mechanism: Novel (Non-Kinase)
Indication: Atopic Dermatitis +
ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is currently in Phase 1 clinical trials.
Mechanism: NLRP3/TL1A Pathway+ Inhibitor
Indication: Inflammatory Bowel Disease
ESN-X is a first-in-class, gut-preferred, oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ESN-X has completed IND-enabling studies and is expected to enter Phase 1 trials in 2025.
Mechanism: MRPGRX4 Antagonist
Indication: Cholestatic Pruritus
ESN-C is a potential best-in-class oral MRGPRX4 antagonist to treat the debilitating itch associated with cholestatic conditions. ESN-C has completed IND-enabling studies.
Mechanism: Novel (Hormone Mimetic)
Indication: Obesity
ESN-O is a first-in-class, oral small molecule for the treatment of obesity. In addition to compelling efficacy, ESN-O shows highly encouraging safety and tolerability for long-term use. ESN-O is expected to be in Phase 1 trials in 2025.
Mechanism: NLRP3/TL1A Pathway+ Inhibitor
Indication: Multiple Liver
ESN-X1 is a first-in-class, oral single-target, multi-cytokine inhibitor being studied in multiple liver conditions. ESN-X1 has reached DC and is ready for IND-enabling studies.
Mechanism: Novel
Indication: Idiopathic Pulmonary Fibrosis
ESN-A is a first-in-class, oral small molecule demonstrating potent efficacy in multiple preclinical models of fibrosis. ESN-A has reached DC and is ready for IND-enabling studies.
Mechanism: NLRP3/TL1A Pathway+ Inhibitor
Indication: Multiple Neurological, Obesity
ESN-X2 is a first-in-class, brain-penetrant oral small molecule that offers "multi-biologic in a pill" potential via a novel single target for the treatment of multiple neurological and cardiometabolic disorders. ESN-X2 has reached DC and is ready for IND-enabling studies.
Mechanism: TGR5 Agonist
Indication: Inflammatory Bowel Disease
ESN-D is a potential best-in-class, gut-preferred, oral TGR5 agonist being studied in inflammatory bowel disease. ESN-D has reached DC and is ready for IND-enabling studies.
Mechanism: TGFβ Inhibitor
Indication: Fibrostenotic Crohn's
ESN-Y is a potential best-in-class, gut-preferred, oral TGFβ inhibitor being studied in fibrostenotic Crohn's disease. ESN-Y has reached DC and is ready for IND-enabling studies.
Mechanism: TGFβ Inhibitor
Indication: Derm Fibrosis
ESN-Y1 is a potential best-in-class, locally injected TGFβ inhibitor being studied in multiple derm fibrotic conditions.
Mechanism: TGFβ Inhibitor
Indication: Lung Fibrosis
ESN-Y2 is a potential best-in-class, inhaled TGFβ inhibitor being studied in multiple lung fibrotic conditions. ESN-Y2 is expected to be a DC by end of 2024.
Mechanism: NRF2 Agonist
Indication: Undisclosed
ESN-N is a potential best-in-class, topical NRF2 agonist being studied in various neurosensory conditions. ESN-Y2 is expected to be a DC by end of 2024.
Mechanism: MRGPRX2 Antagonist
Indication: Multiple Inflammatory
ESN-G is a potential best-in-class, oral small molecule being studied in multiple inflammatory diseases. ESN-G is expected to be a DC in early 2025.
Mechanism: Novel
Indication: Chronic Pain
ESN-B/B1 are first-in-class, oral small molecules being studied in multiple chronic pain conditions. ESN-B/B1 are expected to be DCs in 2025.
Mechanism: TL1A Antagonist
Indication: Multiple Inflammatory
ESN-T is a potential best-in-class, oral small molecule inhibitor of TL1A for the treatment of inflammatory bowel disease. Multiple promising scaffolds are in optimization with a DC expected in 2025.
Mechanism: IL-4/13 Antagonist
Indication: Multiple Inflammatory
ESN-F is a potential best-in-class, oral small molecule inhibitor of IL-4/13 for the treatment of multiple inflammatory diseases. Multiple promising scaffolds are in optimization with a DC expected in 2025.
ENV-294 is a first-in-class, oral small molecule, with JAK-inhibitor-like efficacy and IL4/IL13-like safety, targeting atopic dermatitis and other inflammatory conditions. We believe ENV-294 has pipeline-in-a-product potential. ENV-294 is currently in Phase 1 clinical trials.
ESN-X is a first-in-class, gut-preferred, oral small molecule that offers a "multi-biologic in a pill" potential via a novel single target for the treatment of inflammatory bowel disease. ESN-X has completed IND-enabling studies and is expected to enter Phase 1 trials in 2025.
ESN-C is a potential best-in-class oral MRGPRX4 antagonist to treat the debilitating itch associated with cholestatic conditions. ESN-C has completed IND-enabling studies.
ESN-O is a first-in-class, oral small molecule for the treatment of obesity. In addition to compelling efficacy, ESN-O shows highly encouraging safety and tolerability for long-term use. ESN-O is expected to be in Phase 1 trials in 2025.
ESN-X1 is a first-in-class, oral single-target, multi-cytokine inhibitor being studied in multiple liver conditions. ESN-X1 has reached DC and is ready for IND-enabling studies.
ESN-A is a first-in-class, oral small molecule demonstrating potent efficacy in multiple preclinical models of fibrosis. ESN-A has reached DC and is ready for IND-enabling studies.
ESN-X2 is a first-in-class, brain-penetrant oral small molecule that offers "multi-biologic in a pill" potential via a novel single target for the treatment of multiple neurological and cardiometabolic disorders. ESN-X2 has reached DC and is ready for IND-enabling studies.
ESN-D is a potential best-in-class, gut-preferred, oral TGR5 agonist being studied in inflammatory bowel disease. ESN-D has reached DC and is ready for IND-enabling studies.
ESN-Y is a potential best-in-class, gut-preferred, oral TGFβ inhibitor being studied in fibrostenotic Crohn's disease. ESN-Y has reached DC and is ready for IND-enabling studies.
ESN-Y1 is a potential best-in-class, locally injected TGFβ inhibitor being studied in multiple derm fibrotic conditions.
ESN-Y2 is a potential best-in-class, inhaled TGFβ inhibitor being studied in multiple lung fibrotic conditions. ESN-Y2 is expected to be a DC by end of 2024.
ESN-N is a potential best-in-class, topical NRF2 agonist being studied in various neurosensory conditions. ESN-Y2 is expected to be a DC by end of 2024.
ESN-G is a potential best-in-class, oral small molecule being studied in multiple inflammatory diseases. ESN-G is expected to be a DC in early 2025.
ESN-B/B1 are first-in-class, oral small molecules being studied in multiple chronic pain conditions. ESN-B/B1 are expected to be DCs in 2025.
ESN-T is a potential best-in-class, oral small molecule inhibitor of TL1A for the treatment of inflammatory bowel disease. Multiple promising scaffolds are in optimization with a DC expected in 2025.
Development Candidate Declared
THE PROBLEM
Over 10% (30M+) of the US population suffers from atopic dermatitis, commonly known as eczema. Yet, today’s treatments for moderate-to-severe eczema either rely on injectables that pose a significant barrier to patient care or oral therapies that come with potentially serious toxicities. Moreover, despite these treatments, half of all eczema to atopic dermatitis patients respond poorly to therapy.
THE MOLECULE
We are developing a first-in-class medicine that fights inflammation in a new way. This novel mechanism allows it to exert potentially powerful anti-inflammatory effects without the same toxicities that have burdened previous treatments – and can be delivered orally via a pill.
THE PROGRESS
Our molecule has demonstrated robust efficacy comparable to Jak-inhibitors in preclinical atopic dermatitis models but without their concomitant risks as evidenced by pre-clinical safety testing. It is currently in Phase I clinical trials.
THE PROBLEM
Inflammatory bowel disease, or IBD, which includes both Crohn’s disease and Ulcerative Colitis, is a chronic autoimmune disorder that damages the digestive tract and disrupts the lives of more than 3 million people in the United States. IBD has limited treatment options that have proven to cause long-term remission in patients.
Moreover, many safe existing treatments have to be delivered as injections or pills that come with significant safety liabilities.
THE MOLECULE
We are developing a new therapeutic approach to treating IBD. Our first-in-class molecule hits multiple clinically validated pathways simultaneously, has been engineered to be preferentially present in the gut, and can be administered as a convenient pill. With ESN-X, we have the potential to deliver improved safety, efficacy, and convenience.
THE PROGRESS
This powerful molecule is set to enter clinical trials in 2025.
Together, we can rapidly multiply humanity’s knowledge of the natural
world’s chemistry and solve many of the greatest challenges in human
and planetary health. We’d love your support.